Physician profile
Sony Mathews
NPI 1376714519
$8,967.05
in general payments reported to CMS, 2019-2025
36 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $500 · 2021: $930 · 2022: $1,109 · 2023: $1,853 · 2024: $1,600 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,471.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,872.34 | 2019-2025 | |
| Janssen Biotech, INC. | $648.31 | 2020-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $540.41 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.47 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $365.38 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $349.50 | 2021-2025 | Tremfya, Stelara, Remicade |
| Daiichi Sankyo INC. | $289.28 | 2019-2022 | |
| Redhill Biopharma INC. | $245.66 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $197.31 | 2021-2024 | Dificid, Zerbaxa |
| Lilly USA, LLC | $176.10 | 2023-2025 | Omvoh |
| Celgene Corporation | $167.47 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $148.80 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $145.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $139.15 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $132.10 | 2022-2024 | Clenpiq, Rebyota |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $128.69 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $121.64 | 2023 | Zeposia |
| Medtronic, INC. | $104.32 | 2022 | |
| Ironwood Pharmaceuticals, INC | $98.40 | 2021-2022 | |
| Phadia US INC. | $90.60 | 2021 | |
| Celltrion USA INC. | $88.95 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $77.56 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $57.70 | 2022-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $51.88 | 2020-2023 | |
| Qol Medical, LLC | $51.05 | 2022-2023 | Sucraid |
| Braintree Laboratories, INC. | $38.90 | 2021-2023 | Sutab |
| Amgen INC. | $37.98 | 2023-2025 | Avsola, Uplizna |
| Ucb, INC. | $34.16 | 2019 | |
| Organon LLC | $32.03 | 2022-2023 | Renflexis, Hadlima |
| Welch Allyn | $29.52 | 2021 | |
| Alnylam Pharmaceuticals INC. | $24.31 | 2025 | Givlaari |
| Ipsen Biopharmaceuticals, INC | $17.98 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $16.92 | 2020 | |
| Intra-Sana Laboratories | $13.90 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Allergan, INC. | $13.58 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sony Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.